Arix Bioscience (ARIX) Share Price, News & Analysis

Company Overview

Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, novel therapeutics, innovative technologies, medical innovation comprising healthcare and life sciences. It seeks to invest globally. The firm employs an evergreen approach to funding. It primarily makes investments from its own balance sheet. The firm prefers to take board seat. The firm exit when the optimum value has been reached. Arix Bioscience plc is formerly known as Perceptive Bioscience Investments Limited. Arix Bioscience plc was founded in 2015 and is based in London, United Kingdom.

Key Stats

• Today's Range: 142 to 142
• 50-Day Range: 142 to 142
• 52-Week Range: 97 to 145
• Volume: 377,046 shs
• Average Volume: 636,934 shs
• Market Capitalization: £183.73 million
• P/E Ratio: 1,290.91
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ARIX Stock Analysis - Frequently Asked Questions

How have ARIX shares performed this year?

Arix Bioscience's stock was trading at GBX 126 on January 1st, 2024. Since then, ARIX shares have increased by 12.7% and is now trading at GBX 142.
View the best growth stocks for 2024 here.

How do I buy shares of Arix Bioscience?

Shares of ARIX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Arix Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Arix Bioscience investors own include Eagle Point Credit (ECC), Venture Life Group (VLG), Antero Resources (AR), Bango (BGO), BATM Advanced Communications (BVC), Gresham House (GHE) and Ivanhoe Mines (IVN).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:ARIX
• CUSIP: N/A
• CIK: N/A
• Web: arixbioscience.com
• Phone: +44-20-72901050
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX 0.11
• Trailing P/E Ratio: 1,290.91
• Forward P/E Ratio: 3.70
• P/E Growth: N/A
• Net Income: £14.96 million
• Net Margins: 105.64%
• Pretax Margin: N/A
• Return on Equity: 6.41%
• Return on Assets: 2.18%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 73.10
• Quick Ratio: 117.67

Sales & Book Value

• Annual Sales: £14.16 million
• Price / Sales: 12.98
• Cash Flow: GBX 136.32 per share
• Price / Cash Flow: 1.04
• Book Value: GBX 192 per share
• Price / Book: 0.74

Miscellaneous

• Outstanding Shares: 129,390,000
• Free Float: N/A
• Market Cap: £183.73 million
• Optionable: Not Optionable
• Beta: 1.05